New Innovative Class of Drug Targets Heart Disease
It was welcome news for global people where the professional researchers at the University of Alberta have produced a potent synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes. They are believed that researchers found that a deficiency in the peptide apelin is associated with heart failure, pulmonary hypertension and diabetes. The research unit expediently developed a synthetic version that focus pathways in the heart and promotes blood vessel growth.
The professional researchers conveyed that the synthetic form of apelin is far more stable and potent than the naturally occurring peptide, making drug therapies possible. They also found out that the new group of drugs can be utilized for a numerous variety of disorders, all of which have a huge economic burden on the health-care system.
In addition the research group analyzed apelin deficiency in the hearts of mice and humans through the Human Explanted Heart Program, or HELP. With the HELP program permits for the persuasive study of specimens obtained from patients undergoing a heart transplant.
It is proved that hearts from patients who suffered heart attacks were deficient in apelin, which is required for angiogenesis—the formation of new blood vessels that helps the body adapt after tissue damage from heart attacks.
In conclusion the research team has filed a provisional patent on the synthetic apelin and would continue work developing the drug to be more potent and clinically applicable. It is also suggested that they have conducting potent clinical trials successfully and soon be released.
The study was published in the August issue of the Journal of the American Heart Association. The Oudit’s research was funded by the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada and Alberta Innovates – Health Solutions.